Total Payments
$21,460
2024 Payments
$1,853
Companies
56
Transactions
182
Medicare Patients
6,626
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$7,725 (36.0%)
Food & Beverage$6,717 (31.3%)
Consulting$6,665 (31.1%)
Education$326.89 (1.5%)
Travel$25.68 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,717 | 167 | 31.3% |
| Consulting Fee | $6,665 | 3 | 31.1% |
| Honoraria | $4,550 | 1 | 21.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,175 | 3 | 14.8% |
| Education | $326.89 | 7 | 1.5% |
| Travel and Lodging | $25.68 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $7,150 | 14 | $0 (2024) |
| Novocure Inc. | $4,693 | 5 | $0 (2023) |
| Heron Therapeutics, Inc. | $3,136 | 2 | $0 (2017) |
| Celgene Corporation | $473.11 | 12 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $423.07 | 8 | $0 (2024) |
| Merck Sharp & Dohme LLC | $419.92 | 8 | $0 (2024) |
| Lilly USA, LLC | $387.25 | 8 | $0 (2023) |
| Puma Biotechnology, Inc. | $368.50 | 3 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $323.13 | 4 | $0 (2024) |
| Sirtex Medical Inc | $257.66 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,853 | 58 | GlaxoSmithKline, LLC. ($194.32) |
| 2023 | $5,826 | 32 | Novocure Inc. ($4,670) |
| 2022 | $335.07 | 7 | Monteris Medical Corporation ($134.65) |
| 2021 | $1,607 | 7 | AstraZeneca Pharmaceuticals LP ($1,365) |
| 2020 | $2,542 | 7 | AstraZeneca Pharmaceuticals LP ($2,320) |
| 2019 | $685.11 | 12 | Puma Biotechnology, Inc. ($125.00) |
| 2018 | $1,249 | 37 | Clovis Oncology, Inc. ($189.06) |
| 2017 | $7,363 | 22 | AstraZeneca Pharmaceuticals LP ($3,326) |
All Payment Transactions
182 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $1.35 | General |
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $39.33 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $25.33 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $103.65 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: CELLT | ||||||
| 11/25/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $11.19 | General |
| 11/25/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $3.06 | General |
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $30.91 | General |
| Category: CELLT | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.07 | General |
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.12 | General |
| 10/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $33.37 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $114.14 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $95.41 | General |
| 10/17/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $40.94 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.78 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $23.77 | General |
| 10/07/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,555 | 54,029 | $1.3M | $289,075 |
| 2022 | 34 | 1,377 | 30,191 | $1.1M | $283,272 |
| 2021 | 40 | 1,759 | 31,307 | $1.5M | $432,587 |
| 2020 | 49 | 1,935 | 109,309 | $3.6M | $1.1M |
Total Patients
6,626
Total Services
224,836
Medicare Billing
$2.1M
Procedure Codes
163
All Medicare Procedures & Services
163 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 41 | 51 | $207,519 | $56,528 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 189 | 456 | $125,400 | $42,872 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 126 | 298 | $104,300 | $41,214 | 39.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 65 | 294 | $121,128 | $29,639 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 154 | 218 | $38,150 | $13,766 | 36.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 43 | 80 | $54,480 | $12,983 | 23.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 13 | 1,760 | $49,280 | $10,286 | 20.9% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 83 | 158 | $63,358 | $8,995 | 14.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $21,500 | $7,045 | 32.8% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 13 | 27,961 | $51,343 | $6,973 | 13.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 71 | $17,750 | $6,597 | 37.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 67 | 489 | $34,230 | $5,866 | 17.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 38 | 44 | $19,800 | $4,465 | 22.5% |
| 70491 | Ct scan of soft tissue of neck with contrast | Office | 2023 | 28 | 51 | $20,349 | $4,243 | 20.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 44 | 88 | $16,720 | $4,161 | 24.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 79 | $15,958 | $3,886 | 24.3% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 22 | 74 | $11,840 | $3,535 | 29.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 46 | 155 | $15,500 | $3,462 | 22.3% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 15 | 18 | $14,130 | $2,841 | 20.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 41 | $7,175 | $2,532 | 35.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $7,500 | $2,031 | 27.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 51 | 188 | $11,280 | $2,021 | 17.9% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 35 | 15,900 | $79,500 | $1,930 | 2.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 25 | 90 | $8,370 | $1,875 | 22.4% |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | Office | 2023 | 16 | 152 | $4,560 | $1,788 | 39.2% |
About Dr. Bibas Reddy, D.O
Dr. Bibas Reddy, D.O is a Hematology & Oncology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1457577017.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bibas Reddy, D.O has received a total of $21,460 in payments from pharmaceutical and medical device companies, with $1,853 received in 2024. These payments were reported across 182 transactions from 56 companies. The most common payment nature is "Food and Beverage" ($6,717).
As a Medicare-enrolled provider, Reddy has provided services to 6,626 Medicare beneficiaries, totaling 224,836 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 163 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fort Worth, TX
- Active Since 04/18/2007
- Last Updated 02/06/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457577017
Products in Payments
- TAGRISSO (Drug) $5,626
- SUSTOL (Drug) $3,136
- IMFINZI (Biological) $1,393
- KEYTRUDA (Biological) $419.92
- SIR-Spheres Microspheres (Device) $257.66
- REBLOZYL (Biological) $239.32
- Rubraca (Drug) $189.06
- Revlimid (Drug) $187.13
- OJJAARA (Drug) $176.80
- Onivyde (Drug) $175.82
- LIBTAYO (Biological) $171.26
- Orserdu (Drug) $162.72
- OPDIVO (Biological) $150.65
- Lenvima (Drug) $138.32
- JAKAFI (Drug) $138.04
- NERLYNX (Drug) $135.93
- Neuroblate (Device) $134.65
- Venclexta (Drug) $129.15
- Abraxane (Drug) $128.43
- CYRAMZA (Drug) $126.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fort Worth
Dr. Prasanthi Ganesa, M.d, M.D
Hematology & Oncology — Payments: $225,864
Hematology & Oncology $225,864
Robyn Young, M.d, M.D
Hematology & Oncology — Payments: $145,466
Hematology & Oncology $145,466
Henry Xiong, M.d, M.D
Hematology & Oncology — Payments: $133,941
Hematology & Oncology $133,941
Harris Naina, Md, MD
Hematology & Oncology — Payments: $100,947
Hematology & Oncology $100,947
Asim Ahmad, Md, MD
Hematology & Oncology — Payments: $84,824
Hematology & Oncology $84,824
Timothy Mccavit, Md, MD
Hematology & Oncology — Payments: $48,338
Hematology & Oncology $48,338